相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
Stephan Kadauke et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A. Brown et al.
LEUKEMIA (2021)
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
Marie-Emilie Dourthe et al.
LEUKEMIA (2021)
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Regina M. Myers et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
Martin Stanulla et al.
BLOOD (2020)
Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia
Kristian Lovvik Juul-Dam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Xian Zhang et al.
BLOOD ADVANCES (2020)
Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival
Agne Taraseviciute et al.
BLOOD (2020)
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
George Mo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure
Olivia M. Lucero et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome
Habibe Kurt et al.
MODERN PATHOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia
Matthew J. Oberley et al.
PEDIATRIC BLOOD & CANCER (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches
Amanda C. Winters et al.
FRONTIERS IN PEDIATRICS (2017)
Philadelphia chromosome-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
E. M. C. Driessen et al.
LEUKEMIA (2016)
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia
Julie A. E. Irving et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby et al.
NATURE COMMUNICATIONS (2016)
Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis
Shannon L. Maude et al.
BLOOD (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Intensified Chemotherapy Without Sct in Infant All: Results From COG P9407 (Cohort 3)
ZoAnn E. Dreyer et al.
PEDIATRIC BLOOD & CANCER (2015)
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome
C. J. Harrison et al.
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Secondary Philadelphia chromosome and erythrophagocytosis in a relapsed acute myeloid leukemia after hematopoietic cell transplantation
Katalin Kelemen et al.
CANCER GENETICS (2014)
Safety in numbers: hyperdiploidy and prognosis
William L. Carroll
BLOOD (2013)
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results
Nicole Dastugue et al.
BLOOD (2013)
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL
Arian van der Veer et al.
BLOOD (2013)
Risk-Directed Treatment Intensification Significantly Reduces the Risk of Relapse Among Children and Adolescents With Acute Lymphoblastic Leukemia and Intrachromosomal Amplification of Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 Trials
Anthony V. Moorman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group
Nyla A. Heerema et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Relapsed childhood acute lymphoblastic leukaemia
Deepa Bhojwani et al.
LANCET ONCOLOGY (2013)
Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor
A. Enshaei et al.
LEUKEMIA (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Lineage switch in childhood acute leukemia: An unusual event with poor outcome
Jorge G. Rossi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling
Lilian Kuster et al.
BLOOD (2011)
Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia
Frederik W. van Delft et al.
BLOOD (2011)
Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols
Mette K. Andersen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations
J. Davidsson et al.
LEUKEMIA (2010)
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia.
Charles G. Mullighan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Outcome of Recurrent or Refractory Acute Lymphoblastic Leukemia in Infants With MLL Gene Rearrangements: A Report From the Japan Infant Leukemia Study Group
Daisuke Tomizawa et al.
PEDIATRIC BLOOD & CANCER (2009)
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Charles G. Mullighan et al.
SCIENCE (2008)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute consortium protocol 95-01
Mignon L. Loh et al.
BLOOD (2006)
High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative
MJ Sutcliffe et al.
LEUKEMIA (2005)
Mechanisms of disease: Acute lymphoblastic leukemia
C Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
CH Pui et al.
LANCET (2002)
分享论文
